
MGI Tech Co. issued a statement detailing the use of its technology in improving the rates of genomic sequencing in South Africa.
Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.

MGI Tech Co. issued a statement detailing the use of its technology in improving the rates of genomic sequencing in South Africa.

An unexpected consequence of the COVID 19 pandemic has been a loss in trust of vaccines. Over the past three flu seasons, there has been a drop in vaccination rates that is alarming experts. Dr. Gregg Sylvester, chief health officer at CSL Seqirus, spoke with Pharmaceutical Executive about the causes of the decline and how important it is to get the rates back to normal.

The partnership will allow both group to expand their operations and provide more solutions to underserved communities.

The lead transformation evangelist at Celonis discusses how digital twins are becoming more prominent in the pharma industry.

Biocon Biologic ’s chief commercial officer of advanced markets discusses the current market and potential trends for biosimilars.

The PBM defined its core values and what role it believes PBMS should play in the industry.

The deals leader at EY Global Life Sciences discusses how the first half of 2024 fared compared to 2023’s strong ending.

The company received the money through a government project agreement.

The AI-powered feature will provide detailed nutritional information based on photos of food taken by users.

Dx&Vx identified multiple potential drug candidates using AI-based technology.

The two companies will continue to collaborate on the use of machine learning in improving precision medicine development.

This is the latest approval for Phathom Pharmaceutical’s GI treatment.

The tech company’s data platform will be implemented into the genomic research department’s workflow.

The network includes organizations that represent over 45,000 agents and brokers.

Ripston discusses the Biospecimen Management Consortium and how its working to develop best practices for driving sample excellence.

The two companies will use Astrana’s technology offerings to improve access.

EVERSANA’s senior vice president of innovation discusses how the technology has been implemented in various areas of the pharmaceutical industry.

The global president of endomechanical and energy for Johnson & Johnson MedTech discusses the need for multidisciplinary care when treating obesity.

Empara’s virtual assistant is the latest attempt to use AI to simplify the user experience in the healthcare industry.

The AscellaHealth CEO discusses how new technologies are increasing the options in patient care.

The CEO of Revelation Pharma discusses how compounding pharmacies may help solve the ongoing issue with drug shortages.

Dr. Varshney discusses how AI is being used to sort data and discover new molecules and indications for existing drugs.

The compounding pharmacy acquired Taylors Pharmacy and Key Compounding Pharmacy.

Body Vision’s AI-powered LungVision image system earned a place in Vizient’s innovative technology program.

The company announced that it had received certification from BSI Medical Devices.

MTX325 is in Phase I trials and is believed to be able to modify the course of the disease.

The platform is similar to other recent digital platforms in that it is designed to reduce drug costs.

The company announced that it has partnered with Adena Health and The Ohio State University Health Plan Solutions.

Patients who received PrimeC reportedly saw significant impact to the disease’s progression.

As previously announced, Michael assumed the role on July 1.